HC Wainwright Issues Pessimistic Forecast for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Rockwell Medical in a report released on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.08) per share for the year, down from their prior estimate of ($0.05). HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.05) per share.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). Rockwell Medical had a negative net margin of 7.98% and a negative return on equity of 15.41%. The business had revenue of $17.34 million during the quarter, compared to analysts’ expectations of $17.95 million.

A number of other research firms also recently commented on RMTI. Wall Street Zen raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $2.00.

Rockwell Medical Trading Up 0.6%

NASDAQ:RMTI opened at $0.84 on Wednesday. The company has a quick ratio of 3.63, a current ratio of 3.74 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $0.91 and its two-hundred day moving average is $0.96. Rockwell Medical has a 52 week low of $0.74 and a 52 week high of $2.10. The company has a market cap of $33.28 million, a PE ratio of -5.62 and a beta of 1.65.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RMTI. XTX Topco Ltd lifted its holdings in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares during the last quarter. Jane Street Group LLC bought a new position in Rockwell Medical during the 4th quarter worth approximately $84,000. GSA Capital Partners LLP lifted its holdings in shares of Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after purchasing an additional 141,672 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after purchasing an additional 41,668 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.